The life cycle of evidence for novel chemotherapeutic agents in advanced non-small cell lung cancer
Martin Neil Reaume
University of Ottawa (Canada)
2006
A phase I study of nivolumab (anti-PD-1; BMS-936558; ONO-4538) in combination with sunitinib, pazopanib, or ipilimumab in patients (pts) with metastatic renal cell carcinoma (mRCC).
Asim Amin , Marc S. Ernstoff , Jeffrey R. Infante , Daniel Yick Chin Heng
Journal of Clinical Oncology 31
15
2013
Simone-simulation in medical oncology education: Part I—Pilot feasibility study.
Shelly Sud , John Kim , Olivia Petersons , Xinni Song
Journal of Clinical Oncology 32
2014
Randomized phase III trial of adjuvant pazopanib versus placebo after nephrectomy in patients with locally advanced renal cell carcinoma (RCC) (PROTECT).
Robert J. Motzer , Naomi B. Haas , Frede Donskov , Marine Gross-Goupil
Journal of Clinical Oncology 35 ( 15_suppl) 4507 -4507
29
2017
Cost-utility of Sunitinib Versus Pazopanib in Metastatic Renal Cell Carcinoma in Canada using Real-world Evidence.
Sara Nazha , Simon Tanguay , Anil Kapoor , Michael Jewett
Clinical Drug Investigation 38 ( 12) 1155 -1165
2
2018
Economic evaluation of erythropoiesis‐stimulating agents for anemia related to cancer
Scott Klarenbach , Braden Manns , Tony Reiman , Martin Neil Reaume
Cancer 116 ( 13) 3224 -3232
11
2010
Utilization and safety of ipilimumab plus nivolumab in a real-world cohort of metastatic renal cell carcinoma patients
Myuran Thana , Naveen S Basappa , Sunita Ghosh , Christian K Kollmannsberger
Clinical Genitourinary Cancer 20 ( 3) 210 -218
3
2022
Testosterone suppression plus enzalutamide versus testosterone suppression plus standard antiandrogen therapy for metastatic hormone-sensitive prostate cancer (ENZAMET): an international, open-label, randomised, phase 3 trial
Christopher J Sweeney , Andrew J Martin , Martin R Stockler , Stephen Begbie
The Lancet Oncology 24 ( 4) 323 -334
60
2023
199 The Cancer of the Bladder Risk Assessment (COBRA) score accurately predicts cancer-specific survival after radical cystectomy: external validation and lymphovascular invasion assessment value to improve its performance Anna Colomer Gallardo, Luigi Candela, Oscar Buisan Rueda, Roger Freixa Sala, Javier Elias Cañavera
Marco Moschini , Petr Macek , Mostefa Bennamoun , Annick Mombet
Attitudes towards open‐label versus placebo‐control designs in oncology randomized trials: A survey of medical oncologists
Igal Kushnir , Mark Clemons , Dean Fergusson , Dominick Bossé
Journal of Evaluation in Clinical Practice 28 ( 3) 495 -499
2
2022
The need for speed in advanced non‐small cell lung cancer: a population kinetics assessment
David J Stewart , Donna E Maziak , Sara M Moore , Stephanie Y Brule
Cancer Medicine 10 ( 24) 9040 -9046
13
2021
Canadian Cancer Trials Group (CCTG) IND215: A phase Ib study of Selumetinib in patients with untreated advanced or metastatic NSCLC who are receiving standard chemotherapy regimens.
J. R. Goffin , G. Nicholas , M. Mates , D. Tu
Investigational New Drugs 37 ( 3) 498 -506
4
2019
Efficacy and compliance of small-bore chest tube insertion and pleurodesis protocols for the treatment of malignant pleural effusions
R. A. Goodwin , M. Reaume , V. Gallant , G. MacArtney
Journal of Clinical Oncology 25 ( 18_suppl) 19575 -19575
2007
A phase II study of single agent abraxane as second-line therapy in patients with advanced urothelial carcinoma
S. S. Sridhar , C. M. Canil , A. Eisen , I. F. Tannock
Journal of Clinical Oncology 27 ( 15_suppl) e16058 -e16058
4
2009
The risk of venous thromboembolism in renal cell carcinoma patients with residual tumor thrombus.
R. Ihaddadene , D. W. Yokom , G. Le Gal , P. Moretto
Journal of Thrombosis and Haemostasis 12 ( 6) 855 -859
8
2014
Increased risk of preoperative venous thromboembolism in patients with renal cell carcinoma and tumor thrombus.
D. W. Yokom , R. Ihaddadene , P. Moretto , C. M. Canil
Journal of Thrombosis and Haemostasis 12 ( 2) 169 -171
9
2014
Use of targeted therapy in patients with metastatic renal cell carcinoma: clinical and economic impact in a Canadian real-life setting
S. Nazha , S. Tanguay , A. Kapoor , M. Jewett
Current Oncology 25 ( 6) 576 -584
10
2018
P-227 Concurrent chemoradiotherapy with cisplatin and vinorelbine in locally advanced non-small cell lung cancer
X. Song , V. Gallant , S. Laurie , G. Nicholas
Lung Cancer 49
2005
IND.175: Phase I study of daily oral AZD2171, a vascular endothelial growth factor receptor inhibitor (VEGFRI), in combination with gemcitabine and cisplatin (G/C) in patients with advanced non-small cell lung cancer (ANSCLC): A study of the NCIC Clinical Trials Group
G. D. Goss , S. Laurie , F. Shepherd , N. Leighl
Journal of Clinical Oncology 25 7649 -7649
21
2007
Phase I study of temozolomide in conjunction with gemcitabine
R. Goel , S. Gertler , D. J. Stewart , S. Laurie
Journal of Clinical Oncology 22 2127 -2127
2004